Inotuzumab ozogamicin
Besponsa (inotuzumab ozogamicin) is an intravenous prescription drug, supplied as a lyophilized powder for injection. It's an immunoconjugate that targets CD22 on cancer cells, leading to DNA damage and cell death. Manufactured by Wyeth Pharmaceuticals LLC (a Pfizer subsidiary), it's used in treating relapsed or refractory acute lymphoblastic leukemia. This information was generated using AI and is provided for informational and research purposes only.
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | Besponsa (inotuzumab ozogamicin) is an intravenous prescription drug, supplied as a lyophilized powder for injection. It's an immunoconjugate that targets CD22 on cancer cells, leading to DNA damage and cell death. Manufactured by Wyeth Pharmaceuticals LLC (a Pfizer subsidiary), it's used in treating relapsed or refractory acute lymphoblastic leukemia. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Inotuzumab ozogamicin",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Inotuzumab ozogamicin — ANDA 761040 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761040"
}
]
|
| identifier | ANDA761040 |
| issued | 2016-09-16 |
| keyword |
[
"drug-manufacturers",
"fda",
"health-care",
"medications",
"public-health"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Inotuzumab ozogamicin |
